Patient Profile and Treatment Characteristics of Early Ritlecitinib Initiators in the US

November 2024 in “ SKIN The Journal of Cutaneous Medicine ”

Samantha K. Kurosky, Liza Takiya, Kent Hanson, Griffith Bell, Y C Lee, Genevieve Gauthier

ritlecitinib Alopecia Areata alopecia totalis alopecia universalis systemic immunomodulators corticosteroids autoimmune disorders atopic disorders

TLDR Ritlecitinib provides new treatment options for diverse alopecia areata patients.

This study examined the early use of ritlecitinib, a treatment for severe alopecia areata (AA), in the US following its FDA approval in June 2023. The retrospective observational study included 150 patients aged 12 and older, analyzing their treatment history and comorbidities. Results showed that 72% of prescriptions were made by dermatologists, with 52% of patients being adolescents and over half being female. A significant portion of patients had alopecia totalis/universalis or other autoimmune, atopic, or mental/emotional disorders. Prior to ritlecitinib, 34% of adolescents and 24% of adults had not received AA treatments. The study suggests that ritlecitinib offers new opportunities for engaging in AA care across diverse patient profiles.

View this study on skin.dermsquared.com →

Discuss this study in the Community →

Similar Research

5 / 108 results

Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

January 2024 in “American journal of clinical dermatology”

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

research Janus Kinase Inhibitors in the Treatment of Alopecia Areata

2 citations, January 2023 in “Prague Medical Report”

JAK inhibitors, like baricitinib, are effective and safe for treating alopecia areata.

Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database

research Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database

1 citations, June 2023 in “Dermatology and therapy”

People with Alopecia Areata have more herpes simplex infections but similar rates of cancer, blood clots, and heart disease compared to those without it.

Disease Burden, Clinical Management, and Unmet Treatment Need of Patients With Moderate to Severe Alopecia Areata: Consensus Statements, Insights, and Practices From CERTAAE Delphi Panel

research Disease Burden, Clinical Management, and Unmet Treatment Need of Patients With Moderate to Severe Alopecia Areata: Consensus Statements, Insights, and Practices From CERTAAE Delphi Panel

April 2024 in “Frontiers in medicine”

Alopecia Areata significantly lowers quality of life and current treatments are inadequate, highlighting a need for better therapies and standardized treatment protocols.

research Baricitinib for the Treatment of Alopecia Areata

6 citations, May 2023 in “Drugs”

Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.